JAK1 and poikiloderma with neutropenia: Phase 2 clinical trials of two JAK1 inhibitors, abrocitinib (NCT05038982) and povorcitinib (NCT05061693), for the treatment of PN, as well as a phase 3 clinical trial of ruxolitinib cream (a JAK1/JAK2 inhibitor) are currently underway (NCT05755438 and NCT05764161).